


RVAC Medicines and A*STAR to build capabilities for mRNA production in Singapore

21 November 2022 | News

Setting up a joint laboratory based at A*STAR's Bioprocessing Technology Institute to develop a preclinical manufacturing platform



RVAC Medicines, a messenger RNA (mRNA) technology platform startup incubated by CBC Group, a healthcare-dedicated asset management firm headquartered in Singapore, and the Agency for Science, Technology and Research (A*STAR) have announced the signing of a master research collaboration agreement to jointly study and develop solutions to build mRNA manufacturing and analytics capabilities in Singapore.

With this collaboration, RVAC and A*STAR will set up a joint laboratory based at A*STAR's Bioprocessing Technology Institute (BTI) to develop a preclinical manufacturing platform, which will facilitate the generation of novel raw materials and potentially clinical-grade assets for the development of mRNA vaccines and therapeutics targeting infectious diseases and other conditions with unmet needs.

Leveraging BTI's deep expertise in processing technologies and analytical sciences for biotherapeutics and the strong translational research in biomedical technologies across multiple research institutes in A*STAR, this collaboration seeks to enable local ecosystem innovators and global manufacturers to access the manufacturing platform to aid in preclinical asset development.

The collaboration utilises RVAC's extensive capabilities in mRNA, vaccine, and drug delivery technologies, as well as knowledge and expertise in biopharmaceutical manufacturing, research and development (R&D), clinical development, and commercialisation.